“Targeting RAS and mutant p53: Discovery of RNA splicing as a therapeutic vulnerability in pancreatic cancer”

We recently discovered a novel mechanism of cooperation between the two most common oncogenes in pancreatic cancer, oncogenic RAS and mutant p53, uncovering a potential therapeutic opportunity to target tumors that bear these mutations. We expect to identify novel and specific dependencies of pancreatic cancer cells by targeting alternatively spliced products and/or manipulating the function of splicing factors in the background of multiple forms of mutated TP53, to provide the foundation for future research that will lead to the development of more effective approaches to treat pancreatic cancer, improving survival and quality of life.

Tuesday
November 13, 2018
4:00 p.m.

Luisa Escobar-Hoyos
Postdoctoral Research Fellow
Memorial Sloan Kettering Cancer Center
Research Assistant Professor
Stony Brook University

This lecture series features the most promising young scientists who are making notable discoveries as postdoctoral fellows or early career faculty.